{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T11:10:35Z","timestamp":1770117035977,"version":"3.49.0"},"reference-count":35,"publisher":"Georg Thieme Verlag KG","funder":[{"name":"Rodrigo Arreola-D\u00edaz received a scholarship from Consejo Nacional de Ciencia y Tecnolog\u00eda","award":["CONACYT:585494"],"award-info":[{"award-number":["CONACYT:585494"]}]},{"name":"Programa Institucional de Formaci\u00f3n de Investigadores del Instituto Polit\u00e9cnico Nacional","award":["BEIFI:A180331"],"award-info":[{"award-number":["BEIFI:A180331"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hamostaseologie"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hemophilia A is a hemorrhagic disease caused by a quantitative\/qualitative deficiency of factor VIII. It is classified as severe, moderate, or mild based on its residual procoagulant activity. Long-term administration of FVIII promotes the development of neutralizing antibodies (inhibitors) in almost 30% of patients with the severe form of the disease. Currently, the role of regulatory T cells in the development of these antibodies is conflicting. Accordingly, the aim of this study was to determine the percentage of regulatory T cells subpopulations by flow cytometry in 10 healthy subjects, 15 patients with severe hemophilia without inhibitors, and 8 with inhibitors. No significant differences in the frequency of regulatory T cells subpopulations were found between hemophilia A patients with inhibitors versus hemophilia A patients without inhibitors or healthy subjects. Our results suggest that the role of the regulatory T cells populations on the development of inhibitors in adult patients with hemophilia A is questionable. However, further analysis of the etiological relevance of these cells requires future research.<\/jats:p>","DOI":"10.1055\/a-2698-0263","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T23:50:12Z","timestamp":1770076212000},"source":"Crossref","is-referenced-by-count":0,"title":["Frequency of T Regulatory Cells Subpopulations in Hemophilia A Patients with Inhibitors"],"prefix":"10.1055","author":[{"given":"Rodrigo","family":"Arreola-D\u00edaz","sequence":"additional","affiliation":[{"name":"Unidad de Investigaci\u00f3n M\u00e9dica en Trombosis, Hemostasia y Aterog\u00e9nesis, Instituto Mexicano del Seguro Social, Mexico City, Mexico"},{"name":"Departamento de Inmunologia, Escuela Nacional de Ciencias Biologicas, Instituto Politecnico Nacional, Mexico City, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas","family":"Hern\u00e1ndez-Ju\u00e1rez","sequence":"additional","affiliation":[{"name":"CONACYT-Centro Interdisciplinario de Investigaci\u00f3n para el Desarrollo Integral Regional, Unidad Oaxaca, Instituto Polit\u00e9cnico Nacional, Santa Cruz Xoxocotl\u00e1n, Oaxaca, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tania","family":"Ricardo-Moreno","sequence":"additional","affiliation":[{"name":"Unidad de Investigaci\u00f3n M\u00e9dica en Trombosis, Hemostasia y Aterog\u00e9nesis, Instituto Mexicano del Seguro Social, Mexico City, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luvia E.","family":"S\u00e1nchez-Torres","sequence":"additional","affiliation":[{"name":"Departamento de Inmunologia, Escuela Nacional de Ciencias Biologicas, Instituto Politecnico Nacional, Mexico City, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaime","family":"Garc\u00eda-Ch\u00e1vez","sequence":"additional","affiliation":[{"name":"Servicio de Hematologia, Unidad Medica de Alta Especialidad, Hospital de Especialidades Eduardo Fraga Mouret, Centro Medico Nacional La Raza, Instituto Mexicano del Seguro Social, Mexico City, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Vela-Ojeda","sequence":"additional","affiliation":[{"name":"Servicio de Hematologia, Unidad Medica de Alta Especialidad, Hospital de Especialidades Eduardo Fraga Mouret, Centro Medico Nacional La Raza, Instituto Mexicano del Seguro Social, Mexico City, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00edctor Manuel","family":"Dom\u00ednguez-Reyes","sequence":"additional","affiliation":[{"name":"Unidad de Investigaci\u00f3n M\u00e9dica en Trombosis, Hemostasia y Aterog\u00e9nesis, Instituto Mexicano del Seguro Social, Mexico City, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abraham","family":"Majluf-Cruz","sequence":"additional","affiliation":[{"name":"Unidad de Investigaci\u00f3n M\u00e9dica en Trombosis, Hemostasia y Aterog\u00e9nesis, Instituto Mexicano del Seguro Social, Mexico City, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2026,2,2]]},"reference":[{"issue":"03","key":"ref1","first-page":"308","article-title":"Hemofilia","volume":"149","author":"J Garc\u00eda-Ch\u00e1vez","year":"2013","journal-title":"Gac Med Mex"},{"key":"ref2","first-page":"19","article-title":"Chapter 2: Comprehensive care of hemophilia. WFH Guidelines for the Management of Hemophilia, 3rd edition","volume":"26","author":"E Santagostino","year":"2020","journal-title":"Haemophilia"},{"issue":"S 06","key":"ref3","first-page":"95","article-title":"Chapter 8: Inhibitors to clotting factor","volume":"26","author":"M V Ragni","year":"2020","journal-title":"Haemophilia"},{"issue":"06","key":"ref4","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/j.1365-2516.2011.02568.x","article-title":"Factor VIII inhibitors: a 50-year perspective","volume":"17","author":"D Green","year":"2011","journal-title":"Haemophilia"},{"issue":"09","key":"ref5","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/12483","article-title":"Catalytic activity of antibodies against factor VIII in patients with hemophilia A","volume":"5","author":"S Lacroix-Desmazes","year":"1999","journal-title":"Nat Med"},{"issue":"S 06","key":"ref6","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1365-2516.2006.01360.x","article-title":"Basic aspects of inhibitors to factors VIII and IX and the influence of non-genetic risk factors","volume":"12","author":"J Astermark","year":"2006","journal-title":"Haemophilia"},{"issue":"02","key":"ref7","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1182\/blood-2008-02-124941","article-title":"Dynamics of factor VIII interactions determine its immunologic fate in hemophilia A","volume":"112","author":"S Lacroix-Desmazes","year":"2008","journal-title":"Blood"},{"issue":"05","key":"ref8","first-page":"723","article-title":"Cell interactions in the induction of tolerance: the role of thymic lymphocytes","volume":"18","author":"R K Gershon","year":"1970","journal-title":"Immunology"},{"issue":"03","key":"ref9","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.4049\/jimmunol.155.3.1151","article-title":"Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases","volume":"155","author":"S Sakaguchi","year":"1995","journal-title":"J Immunol"},{"issue":"06","key":"ref10","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1002\/eji.201141578","article-title":"Cyclic AMP underpins suppression by regulatory T cells","volume":"42","author":"J Bodor","year":"2012","journal-title":"Eur J Immunol"},{"issue":"01","key":"ref11","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/eji.202048746","article-title":"Cross talk between human regulatory T cells and antigen-presenting cells: lessons for clinical applications","volume":"51","author":"C M Wardell","year":"2021","journal-title":"Eur J Immunol"},{"issue":"07","key":"ref12","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nri2343","article-title":"How regulatory T cells work","volume":"8","author":"D AA Vignali","year":"2008","journal-title":"Nat Rev Immunol"},{"issue":"01","key":"ref13","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.4238\/2014.March.17.5","article-title":"Higher frequency of CD4(+)CD25(high) Treg cells in hemophilia patients with factor VIII inhibitor","volume":"13","author":"K Y Ding","year":"2014","journal-title":"Genet Mol Res"},{"issue":"01","key":"ref14","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/MBC.0000000000000377","article-title":"Assessment of the frequency of regulatory T cells (CD4+CD25+CD127-) in children with hemophilia A: relation to factor VIII inhibitors and disease severity","volume":"27","author":"M A El-Asrar","year":"2016","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"05","key":"ref15","doi-asserted-by":"crossref","first-page":"e557","DOI":"10.1097\/HS9.0000000000000557","article-title":"Role of regulatory cells in immune tolerance induction in hemophilia A","volume":"5","author":"S J Schep","year":"2021","journal-title":"HemaSphere"},{"issue":"06","key":"ref16","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/ijlh.14139","article-title":"Altered frequency of FOXP3+ regulatory T cells is associated with development of inhibitors in patients with severe hemophilia A","volume":"45","author":"N Arandi","year":"2023","journal-title":"Int J Lab Hematol"},{"issue":"04","key":"ref17","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1182\/blood-2008-04-150524","article-title":"CD49d provides access to \u201cuntouched\u201d human Foxp3+ Treg free of contaminating effector cells","volume":"113","author":"M Kleinewietfeld","year":"2009","journal-title":"Blood"},{"issue":"10","key":"ref18","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1007\/s00262-015-1729-x","article-title":"Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry","volume":"64","author":"S JAM Santegoets","year":"2015","journal-title":"Cancer Immunol Immunother"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1387975","DOI":"10.3389\/fimmu.2024.1387975","article-title":"Regulation of Treg cells by cytokine signaling and co-stimulatory molecules","volume":"15","author":"Y Zong","year":"2024","journal-title":"Front Immunol"},{"issue":"01","key":"ref20","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1177\/2040620712464509","article-title":"Factor VIII inhibitors in hemophilia A: rationale and latest evidence","volume":"4","author":"C Witmer","year":"2013","journal-title":"Ther Adv Hematol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"100998","DOI":"10.1016\/j.arr.2019.100998","article-title":"Activation of immunosuppressive network in the aging process","volume":"57","author":"A Salminen","year":"2020","journal-title":"Ageing Res Rev"},{"issue":"01","key":"ref22","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s12929-017-0391-3","article-title":"Regulatory T cells induced by B cells: a novel subpopulation of regulatory T cells","volume":"24","author":"C H Chien","year":"2017","journal-title":"J Biomed Sci"},{"issue":"06","key":"ref23","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.immuni.2018.12.001","article-title":"The biology of T regulatory type 1 cells and their therapeutic application in immune-mediated diseases","volume":"49","author":"M G Roncarolo","year":"2018","journal-title":"Immunity"},{"issue":"09","key":"ref24","doi-asserted-by":"crossref","first-page":"4620","DOI":"10.4049\/jimmunol.0903329","article-title":"Cutting edge: human latency-associated peptide+ T cells: a novel regulatory T cell subset","volume":"184","author":"R Gandhi","year":"2010","journal-title":"J Immunol"},{"issue":"05","key":"ref25","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.4049\/jimmunol.1003224","article-title":"CD4+FOXP3+ T regulatory cells in human autoimmunity: more than a numbers game","volume":"187","author":"S A Long","year":"2011","journal-title":"J Immunol"},{"issue":"20","key":"ref26","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.1182\/blood-2012-09-457036","article-title":"Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study","volume":"121","author":"S C Gouw","year":"2013","journal-title":"Blood"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/1479-5876-7-89","article-title":"Human T cells express CD25 and Foxp3 upon activation and exhibit effector\/memory phenotypes without any regulatory\/suppressor function","volume":"7","author":"M Kmieciak","year":"2009","journal-title":"J Transl Med"},{"issue":"23","key":"ref28","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1182\/blood-2017-05-782912","article-title":"Marginal zone B cells are critical to factor VIII inhibitor formation in mice with hemophilia A","volume":"130","author":"P E Zerra","year":"2017","journal-title":"Blood"},{"issue":"11","key":"ref29","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1111\/j.1538-7836.2009.03571.x","article-title":"Splenic marginal zone antigen-presenting cells are critical for the primary allo-immune response to therapeutic factor VIII in hemophilia A","volume":"7","author":"A Navarrete","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"13","key":"ref30","doi-asserted-by":"crossref","first-page":"e2025197118","DOI":"10.1073\/pnas.2025197118","article-title":"PPAR\u03b3 marks splenic precursors of multiple nonlymphoid-tissue Treg compartments","volume":"118","author":"C Li","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"03","key":"ref31","doi-asserted-by":"crossref","first-page":"832","DOI":"10.4049\/jimmunol.1500759","article-title":"Circulating follicular regulatory T cells are defective in multiple sclerosis","volume":"195","author":"T Dhaeze","year":"2015","journal-title":"J Immunol"},{"issue":"05","key":"ref32","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.4049\/jimmunol.1701800","article-title":"Targeting antigen-specific B cells using antigen-expressing transduced regulatory T cells","volume":"201","author":"A-H Zhang","year":"2018","journal-title":"J Immunol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"693","DOI":"10.3389\/fimmu.2020.00693","article-title":"Suppression of FVIII-specific memory B cells by chimeric BAR receptor-engineered natural regulatory T cells","volume":"11","author":"A P Pohl","year":"2020","journal-title":"Front Immunol"},{"issue":"18","key":"ref34","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1182\/bloodadvances.2018018556","article-title":"Engineered FVIII-expressing cytotoxic T cells target and kill FVIII-specific B cells in vitro and in vivo","volume":"2","author":"K Parvathaneni","year":"2018","journal-title":"Blood Adv"},{"issue":"04","key":"ref35","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1177\/1076029617702244","article-title":"Regulatory B cells are functionally impaired in patients having hemophilia A with inhibitors","volume":"24","author":"M R Boulassel","year":"2018","journal-title":"Clin Appl Thromb Hemost"}],"container-title":["H\u00e4mostaseologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2698-0263.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T23:50:20Z","timestamp":1770076220000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2698-0263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":35,"URL":"https:\/\/doi.org\/10.1055\/a-2698-0263","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0720-9355","2567-5761"],"issn-type":[{"value":"0720-9355","type":"print"},{"value":"2567-5761","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,2]]}}}